$1.79 EPS Expected for Johnson & Johnson (JNJ) This Quarter
Analysts expect Johnson & Johnson (NYSE:JNJ) to announce $1.79 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $1.75 and the highest estimate coming in at $1.84. Johnson & Johnson posted earnings of $1.68 per share during the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The business is expected to issue its next earnings report before the market opens on Tuesday, October 17th.
On average, analysts expect that Johnson & Johnson will report full year earnings of $7.18 per share for the current fiscal year, with EPS estimates ranging from $7.11 to $7.22. For the next fiscal year, analysts anticipate that the business will post earnings of $7.71 per share, with EPS estimates ranging from $7.50 to $7.90. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the firm earned $1.74 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year.
Several equities research analysts recently issued reports on the company. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Royal Bank Of Canada restated a “buy” rating and issued a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. UBS AG reiterated a “buy” rating and set a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target on the stock in a research report on Thursday, July 27th. Finally, Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Six investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $135.52.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.67% during midday trading on Friday, reaching $132.10. 3,888,431 shares of the company’s stock were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company’s 50-day moving average is $132.31 and its 200-day moving average is $129.75. The stock has a market cap of $354.56 billion, a P/E ratio of 22.35 and a beta of 0.78.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after acquiring an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.